HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

When should fixed ratio basal insulin/glucagon-like peptide-1 receptor agonists combination products be considered?

Abstract
Diabetes management with achievement and maintenance of good glycemic control is very challenging in patients requiring multiple daily injections. This article is focusing on broader use of recently approved fixed ratio combination therapies, basal insulin and glucagon-like peptide-1 receptor agonists (GLP1 RA). These combination therapy improve patient compliance and adherence with the therapy, decrease burden of multiple injection, target multiple abnormalities in the pathophysiology of diabetes, decrease postprandial hypoglycemia, assist in weight loss and decrease weight related comorbidities. These combinations were recently approved for use as first injectables after failure of oral agents. Review of combination treatment with existing fixed doses of basal insulin with GLP1 RA opens door for further clinical trials for other dose combinations that can be used, particularly for patients who need higher doses of insulin.
AuthorsJulia David, Vivian Fonseca
JournalJournal of diabetes and its complications (J Diabetes Complications) Vol. 33 Issue 12 Pg. 107473 (12 2019) ISSN: 1873-460X [Electronic] United States
PMID31668591 (Publication Type: Editorial)
CopyrightCopyright © 2019 Elsevier Inc. All rights reserved.
Chemical References
  • Blood Glucose
  • Drug Combinations
  • Glucagon-Like Peptide-1 Receptor
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • IDegLira
  • Insulin
  • Insulin, Long-Acting
  • Liraglutide
Topics
  • Algorithms
  • Blood Glucose (drug effects, metabolism)
  • Choice Behavior
  • Clinical Trials as Topic (methods)
  • Diabetes Mellitus, Type 2 (blood, drug therapy)
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Glucagon-Like Peptide-1 Receptor (agonists)
  • Glycated Hemoglobin (drug effects, metabolism)
  • Humans
  • Hypoglycemic Agents (administration & dosage)
  • Insulin (administration & dosage)
  • Insulin, Long-Acting (administration & dosage)
  • Liraglutide (administration & dosage)
  • Patient Selection
  • Practice Patterns, Physicians' (statistics & numerical data)
  • Research Design

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: